Clinical Trial Update: A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB) [Phase 2]

View source ↗

Summary

Phase 2 trial update for OPC 67683 in pulmonary sputum culture-positive, multidrug-resistant tuberculosis (TB) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensively Drug-resistant Tuberculosis
• Tuberculosis
• Tuberculosis Multidrug-resistant

Drugs mentioned

• OPC-67683 (delamanid)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Tuberculosis, Pulmonary, Tuberculosis, Multidrug Resistant | Phase 2 | Status: COMPLETED | Results posted: 2021-12-01